Prolonged venous infusion of cisplatin and concurrent radiation therapy for lung carcinoma. A feasibility study

17Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Fifty patients with non resectable and/or inoperable bronchogenic carcinoma were entered into a feasibility study of cisplatin (CDDP) given in continuous infusion with concurrent radiation therapy. The radiation therapy regimen consisted of 2 Gy given 5 days a week in the first 3 and last 2 weeks of a 7‐week split course (50 Gy of total dose). The CDDP (daily dose of 4 to 6 mg/m2) was administered to cover the days of radiation treatment by means of a central venous catheter and a portable pump. Less than 1% of predicted duration of infusion was lost due to complications related to venous access and pump. Toxicity was moderate. The overall probability of a locoregional major response (complete + partial) within 1 month after treatment completion was 86%. Twenty‐three patients underwent resection. The 1‐year actuarial probability of survival was 64%. The high response and survival rates warrant further studies on concurrent CDDP continuous infusion and radiation therapy in inoperable lung carcinoma. Copyright © 1991 American Cancer Society

Cite

CITATION STYLE

APA

Bedini, A. V., Tavecchio, L., Milani, F., Gramaglia, A., Spreafico, C., Marchianò, A., & Ravasi, G. (1991). Prolonged venous infusion of cisplatin and concurrent radiation therapy for lung carcinoma. A feasibility study. Cancer, 67(2), 357–362. https://doi.org/10.1002/1097-0142(19910115)67:2<357::AID-CNCR2820670207>3.0.CO;2-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free